Physician profile
Suni Jacob
NPI 1194709402
$14,697.49
in general payments reported to CMS, 2019-2025
51 companies · $3,524 in 2025
The $3,524 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,006 · 2022: $2,076 · 2023: $2,796 · 2024: $3,296 · 2025: $3,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,595 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,595.41 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,105.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,452.35 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $1,298.94 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,114.41 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,056.36 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $978.75 | 2021-2024 | |
| Amgen INC. | $664.21 | 2021-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $454.95 | 2023-2025 | |
| Esperion Therapeutics, INC. | $360.63 | 2024-2025 | Nexletol |
| Exact Sciences Corporation | $345.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $337.80 | 2021-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $333.81 | 2021-2023 | |
| Astellas Pharma US INC | $310.03 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.11 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $280.51 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suni Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.